^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    TNBCDX®

    Company:
    Reveal Genomics
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    2ms
    TNBC-DX Genomic Test Predicts High pCR in Triple-Negative Breast Cancer with sTILs ≥30% Treated with Neoadjuvant Docetaxel-Carboplatin with/without Pembrolizumab. (SABCS 2024)
    The TNBC-DX genomic test effectively predicts pCR to neoadjuvant TCb ± pembrolizumab in TNBC. Notably, the TNBC-DX pCR-high group identifies patients with high sTILs who have a pCR rate exceeding 90% when treated with TCb+P. This study confirms that gene expression and sTILs provide distinct and potentially complementary information for pCR prediction in TNBC.
    Clinical • PD(L)-1 Biomarker
    |
    BCDx Monitoring Test • TNBCDX®
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel
    3ms
    REVEAL GENOMICS Unveils TNBCDX: the First Genomic Test Designed for Early-stage Triple-Negative Breast Cancer (Businesswire)
    "REVEAL GENOMICS...today announced both the development and the clinical validation of TNBCDX, the first genomic test designed specifically for patients with early-stage TNBC. This dual milestone will be presented at the ESMO Congress 2024 in Barcelona (Spain)...Across two independent validation studies with 418 patients, the TNBCDX scores showed a strong association with pathological complete response (pCR), distant disease-free survival (DDFS), and overall survival (OS), providing a more refined risk stratification. Notably, the TNBCDX test outperformed tumor-infiltrating lymphocytes (TILs) in predicting both pCR and survival outcomes...The results will be presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona (Spain) on Saturday, September 14th."
    P2 data • Observational data
    |
    TNBCDX®